NCT05833763View on ClinicalTrials.gov

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

April 30, 2032

Study Completion Date

April 30, 2037

Conditions
Mantle Cell LymphomaMantle Cell Lymphoma Refractory
Interventions
DRUG

Glofitamab

Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.

DRUG

Pirtobrutinib

Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.

DRUG

Obinutuzumab

Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.

DRUG

Tocilizumab

Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution

Trial Locations (2)

3050

RECRUITING

Peter MacCallum Cancer Centre, Parkville

6009

RECRUITING

Sir Charles Gairdener, Nedlands

All Listed Sponsors
lead

Australasian Leukaemia and Lymphoma Group

OTHER